MedPath

LIVERPOOL SCHOOL OF TROPICAL MEDICINE

🇬🇧United Kingdom
Ownership
-
Established
1898-01-01
Employees
650
Market Cap
-
Website
https://www.lstmed.ac.uk/

Clinical Trials

50

Active:1
Completed:16

Trial Phases

5 Phases

Phase 1:2
Phase 2:4
Phase 3:6
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (37 trials with phase data)• Click on a phase to view related trials

Not Applicable
19 (51.4%)
Phase 3
6 (16.2%)
Phase 4
6 (16.2%)
Phase 2
4 (10.8%)
Phase 1
2 (5.4%)

Urine Pneumococcal Antigen Project

Not yet recruiting
Conditions
Pneumonia
Pneumonia - Bacterial
First Posted Date
2025-09-18
Last Posted Date
2025-09-18
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
350
Registration Number
NCT07181200

Respiratory Health and Wellbeing Post Pulmonary Tuberculosis

Recruiting
Conditions
Tuberculosis (TB)
First Posted Date
2025-09-17
Last Posted Date
2025-09-17
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
50
Registration Number
NCT07178860
Locations
🇬🇧

Liverpool School of Tropical Medicine, Liverpool, United Kingdom

Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge

Not Applicable
Recruiting
Conditions
Malaria
Severe Malaria
Severe Anaemia
Post Discharge
Interventions
Biological: Antimalarial monoclonal antibodies
Drug: Dihydroartemisinin - Piperaquine (DP)
Drug: Placebo PDMC
Biological: Placebo mMAB
First Posted Date
2025-07-24
Last Posted Date
2025-07-24
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
398
Registration Number
NCT07082205
Locations
🇰🇪

HomaBay County Teaching and Referral Hospital, Kisumu, Nyanza, Kenya

🇰🇪

Siaya County Referral Hospital, Kisumu, Nyanza, Kenya

Safety of Antimalarials in the FIRst trimEster

Phase 3
Not yet recruiting
Conditions
Malaria, Pregnancy
Malaria, Antepartum
Malaria (Uncomplicated)
Interventions
Drug: Pyronaridine-artesunate (PA)
Drug: dihydroartemisinin-piperaquine (DP)
First Posted Date
2025-05-08
Last Posted Date
2025-05-08
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
1510
Registration Number
NCT06962319
Locations
🇧🇫

Clinical Research Unit of Nanoro (CRUN), Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest (IRSS-DRO), Nanoro, Burkina Faso

🇰🇪

KEMRI Centre for Global Health Research (CGHR), Kisumu, Kenya

🇲🇱

Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako (USTTB),, Bamako, Mali

Characterising the Loss of Haemostasis in Haemorrhagic Fever With Renal Syndrome

Not yet recruiting
Conditions
Haemorrhagic Fever With Renal Syndrome
First Posted Date
2025-04-25
Last Posted Date
2025-04-25
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
62
Registration Number
NCT06944275
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 10
  • Next

News

Breakthrough Universal Antivenom Developed Using Blood of Man Bitten 200+ Times

Scientists have developed a groundbreaking antivenom using antibodies from Tim Friede, who voluntarily endured over 200 snake bites and 700 venom injections over nearly 20 years.

£10M Investment in AI-Powered Robotic Labs to Accelerate Infectious Disease Treatment Development

Liverpool School of Tropical Medicine receives £10M funding to establish AI-powered robotic Containment Level 3 laboratories for accelerating development of treatments for high-risk infectious diseases.

Nitisinone Shows Promise as Novel Malaria Control Strategy by Making Human Blood Lethal to Mosquitoes

Researchers have discovered that nitisinone, a drug used to treat rare genetic disorders, makes human blood toxic to mosquitoes that transmit malaria, offering a potential new control strategy.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.